Globally, the pulmonary drug delivery market is witnessing growth due to factors such as increasing preference of pulmonary route as an alternate route of drug delivery, rising focus on the development of smart/digital inhalers, and increasing incidence of respiratory diseases such as COPD, asthma, and cystic fibrosis.
The pulmonary drug delivery market is segmented based on formulations, canister type, applications, end users, and regions. Based on applications, the market is segmented into asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and other applications (cardiovascular disease, diabetes, respiratory therapy, and treatment of patients on ventilators). The asthma segment is expected to witness the highest growth during the forecast period due to increasing prevalence of asthma across the globe.
Based on canister type , the market is segmented into plain and coated canister. The coated canister segment is expected to witness the highest growth during majorly due to advantages such as robust profile for filling, avoiding crimping, and withstanding the pressure associated with the type of propellant (HFAs or CFCs).
Based on end user, the pulmonary drug delivery market is segmented into hospitals & clinics and home care settings. In 2016, the home care settings segment is expected to command the largest share of the pulmonary drug delivery market. This growth is majorly attributed to technological advancements in pulmonary drug delivery devices that enable their usage in the home care settings.
Currently, the Asian market is expected to register the highest CAGR during the forecast period due to the rapidly growing geriatric population, growing adoption of an unhealthy lifestyle, growing urbanization, exposure to smoke & chemicals, and the subsequent increase in the prevalence of COPD in the region. Asian region is further segmented into China, India, and Japan. China is the fastest growing market in the Asian region. This is mainly attributed to increasing prevalence of COPD and lung-related diseases, and increasing focus of public and private organizations and associations in the region.
Prominent players in the pulmonary drug delivery market include GlaxoSmithKline (U.K.), Boehringer Ingelheim GmbH (Germany), 3M (U.S.), AstraZeneca plc (U.K.), Merck & Co., Inc. (U.S.), Novartis AG (Switzerland), Omron Corporation (Japan), and Sunovion Pharmaceuticals Inc. (U.S.).